Katherine M. Brendza
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Hepatitis C virus research, HIV Research and Treatment, Hepatitis B Virus Studies, Microtubule and mitosis dynamics
Most-Cited Works
- → Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design(2010)224 cited
- → Autoinhibition of Escherichia coli Rep monomer helicase activity by its 2B subdomain(2005)150 cited
- → E. coli Rep oligomers are required to initiate DNA unwinding in vitro(2001)144 cited
- → The KN-93 Molecule Inhibits Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity by Binding to Ca2+/CaM(2019)114 cited
- → Visualizing ATP-Dependent RNA Translocation by the NS3 Helicase from HCV(2010)106 cited
- → RNase H Active Site Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Design, Biochemical Activity, and Structural Information(2009)96 cited
- → Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition(2020)90 cited
- → Lethal Kinesin Mutations Reveal Amino Acids Important for ATPase Activation and Structural Coupling(1999)90 cited
- → PhosphoethanolamineN-methyltransferase (PMT-1) catalyses the first reaction of a new pathway for phosphocholine biosynthesis inCaenorhabditis elegans(2007)79 cited
- → The 2B domain of the Escherichia coli Rep protein is not required for DNA helicase activity(2002)76 cited